Lysophosphatidic Acid Protects Cancer Cells from Histone Deacetylase (HDAC) Inhibitor-induced Apoptosis through Activation of HDAC
Open Access
- 1 June 2008
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 283 (24) , 16818-16829
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cellsApoptosis, 2006
- HDAC inhibitors: Double edge sword for TRAIL cancer therapy?Cancer Biology & Therapy, 2005
- Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignanciesCell Death & Differentiation, 2004
- Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemiaOncogene, 2003
- Phosphorylation at serine 28 and acetylation at lysine 9 of histone H3 induced by trichostatin AOncogene, 2003
- The emerging role of lysophosphatidic acid in cancerNature Reviews Cancer, 2003
- Histone deacetylases and cancer: causes and therapiesNature Reviews Cancer, 2001
- Homo-oligomerisation and nuclear localisation of mouse histone deacetylase 111Edited by J. KarnJournal of Molecular Biology, 2001
- NuRD and SIN3Trends in Genetics, 2000
- The language of covalent histone modificationsNature, 2000